Home › Neuroendocrine Tumors › Tennessee
Neuroendocrine Tumors clinical trials in Tennessee
7 studies for Neuroendocrine Tumors are looking for participants at sites in Tennessee.
Cities in Tennessee
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Tennessee Medical Center, Knoxville
- Henry-Joyce Cancer Clinic, Nashville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06943755Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- Research Facility, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07165132Project: Every Child for Younger Patients With Cancer
- T C Thompson Children's Hospital, Chattanooga
- East Tennessee Childrens Hospital, Knoxville
- Saint Jude Children's Research Hospital, Memphis
- and 2 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Baptist Memorial Hospital Baptist Cancer Center, Memphis
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Vanderbilt-Ingram Cancer Center, Nashville
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 to 85 · All sexes · Updated Jan 29, 2026 · NCT06055439SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.